Dr Reddys Laboratories (RDY) Liabilities and Shareholders Equity (2009 - 2026)
Dr Reddys Laboratories (RDY) recorded Liabilities and Shareholders Equity of $6.08 billion in the quarter ended Jun 30, 2026, up 0.1% from $6.07 billion a year earlier but down 4.1% from the prior quarter.
Powered by 
Analysis
Dr Reddys Laboratories (RDY) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends
As of Mar 31, 2026, Dr Reddys Laboratories reported Liabilities and Shareholders Equity of $6.18 billion, up 7.0% from the prior year.
- Annual Liabilities and Shareholders Equity has increased for six straight years, with a five-year compound annual growth rate of 11.2% (years ended Mar 2021 to Mar 2026).
- Across earlier years, Liabilities and Shareholders Equity came in at $5.77 billion in the year ended Mar 31, 2025 (+24.1%), $4.65 billion in the year ended Mar 31, 2024 (+18.7%), $3.92 billion in the year ended Mar 31, 2023 (+1.5%) and $3.86 billion in the year ended Mar 31, 2022 (+6.3%).
- Quarterly Liabilities and Shareholders Equity has ranged from $3.65 billion in the quarter ended Sep 30, 2022 to $6.34 billion in the quarter ended Mar 31, 2026 over the past five years.
- On a year-over-year basis, Liabilities and Shareholders Equity has increased for 14 consecutive quarters, with growth averaging 17.2% over the last eight quarters.
- Peak year-over-year performance for Liabilities and Shareholders Equity in the last five years was growth of 32.5% in the quarter ended Sep 30, 2024, against a decline of 2.9% in the quarter ended Sep 30, 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at $6.34 billion (quarter ended Mar 31, 2026), $6.32 billion (quarter ended Dec 31, 2025) and $6.21 billion (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Dr Reddys Laboratories | 10.53 Bn | 9.72 Bn | 396.53 Mn | 6.08 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.08 Bn |
| Mar 31, 2026 | 6.34 Bn |
| Dec 31, 2025 | 6.32 Bn |
| Sep 30, 2025 | 6.21 Bn |
| Jun 30, 2025 | 6.07 Bn |
| Mar 31, 2025 | 5.69 Bn |
| Dec 31, 2024 | 5.70 Bn |
| Sep 30, 2024 | 5.56 Bn |
| Jun 30, 2024 | 4.98 Bn |
| Mar 31, 2024 | 4.67 Bn |
| Dec 31, 2023 | 4.48 Bn |
| Sep 30, 2023 | 4.20 Bn |
| Jun 30, 2023 | 4.08 Bn |
| Mar 31, 2023 | 3.92 Bn |
| Dec 31, 2022 | 3.77 Bn |
| Sep 30, 2022 | 3.65 Bn |
| Jun 30, 2022 | 3.84 Bn |
| Mar 31, 2022 | 3.89 Bn |
| Dec 31, 2021 | 3.77 Bn |
| Sep 30, 2021 | 3.76 Bn |
API Access
Dr Reddys Laboratories Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=RDY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "RDY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=RDY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();